During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]
Yesterday’s post was about the increased risks of developing diabetes faced by men who are on hormone therapy. This study, as well as most others about this topic has looked at the first levels of hormone therapy (ADT) using the traditional drugs like Zoladex, Trelstar, Firmagon, and Lupron. We know very little about the influence [...]
According to a recent study published in the Journal of Urology, men with localized prostate cancer on hormone therapy (ADT) have a significant increase in their risk for developing diabetes. In this retrospective study of 12,191 men with localized prostate cancer who did not have diabetes were followed once they went on ADT. It was [...]
Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
Oh, those weekends, don’t you just love them? They provide us with an opportunity to spend time with our families, drive to the country house or go to the theater. Now, we know they also provide us with an increased opportunity to die in a hospital. Research shows that men with metastatic prostate cancer who [...]
I attend the American Society of Clinical Oncology (ASCO) meeting in Chicago in May. As usual, it was exciting and it provides me with a fantastic opportunity to catch up with the current research in advanced prostate cancer. It also gives me an opportunity to meet with and have private conversations with some of the [...]
JAMA Oncology has published a new study that suggests that adding a statin drug at the initiation of hormone therapy (ADT) to the treatment protocol for a man with progressive, hormone-sensitive prostate cancer may significantly impact their actual time to disease progression (TTP). Historically, we know Statin use has been associated with improved prostate cancer [...]
Click Here to Take the Prostate Cancer Experience The Prostate Cancer Experience study at will help us understand the truth of how prostate cancer treatment affects day to day living. There are many different kinds of treatments, different stages of disease and different sequences of treatment choice making. The Prostate Cancer Experience encompasses all of [...]
The line item for FY 2016 CDC prostate cancer funding of $13,205,000 is restored in both the House and Senate appropriations bills, as authored by their committees. Thanks to the several thousand of you who responded to Malecare's call to action and wrote emails and letters to the Congressional House and Senate Budget Committee. Since both [...]
